Overview

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Human Genome Sciences Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Mapatumumab